Capricor Therapeutics (CAPR) Receivables - Other (2012 - 2024)

Capricor Therapeutics' Receivables - Other history runs 10 years deep, the most recent figure standing at $10.0 million for Q4 2024.

• On a quarterly basis, Receivables - Other changed 0.0% year-over-year to $10.0 million in Q4 2024; TTM through Dec 2024 was $10.0 million, a 0.0% change from a year earlier, with the FY2024 full-year figure at $10.0 million, changed 0.0% from the prior year.
• Receivables - Other steadied at $10.0 million in Q4 2024 per CAPR's latest filing, from $10.0 million in the prior quarter.
• Across five years, Receivables - Other topped out at $10.0 million in Q4 2023 and bottomed at $385.0 in Q2 2020.
• The 4-year median for Receivables - Other is $206000.0 (2021), against an average of $3.0 million.
• Across the five-year window, Receivables - Other retreated 3.45% in 2020 and soared 53406.49% in 2021, its largest moves.
• Year by year, Receivables - Other stood at $56000.0 in 2020, then soared by 267.86% to $206000.0 in 2021, then surged by 4754.37% to $10.0 million in 2023, then changed by 0.0% to $10.0 million in 2024.
• Per Business Quant, the three latest CAPR Receivables - Other figures stand at $10.0 million (Q4 2024), $10.0 million (Q4 2023), and $206000.0 (Q2 2021).